AdAlta is a legitimate ASX-listed biotechnology company (ASX:1AD) developing the proprietary 'i-body' platform for fibrosis and cancer therapeutics. While the underlying technology and problem space possess high utility, this specific submission is of extremely low quality. It contains demonstrably false claims regarding traction ('most people have used my product') and audience reach ('everyone'), which contradict the company's actual status as a clinical-stage entity with no commercial product users. The score reflects the verifiable existence and potential of the technology, heavily penalized for the inaccurate and unprofessional submission data.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline